Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Caulfield

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Frontiers in Endocrinology|April 8, 2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer ImmunotherapyT Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, et al.
The Oncologist|June 7, 2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment OptionsKatherine Emilie Rhoades Smith, Jacqueline Theresa Brown, Limeng Wan, et al.
Urologic Oncology|April 25, 2022
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancerAgreen Hadadi, Katherine Er Smith, Limeng Wan, et al.
The Oncologist|March 13, 2020
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
The Oncologist|November 25, 2022
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsTony Z Zhuang, Deepak Ravindranathan, Yuan Liu, et al.
Cancer Treatment and Research Communications|May 24, 2021
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinibDylan J Martini, Meredith R Kline, Yuan Liu, et al.
Cancer Medicine|February 27, 2020
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitorsJulie M Shabto, Dylan J Martini, Yuan Liu, et al.
Cancer|April 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Yuan Liu, et al.
Therapeutic Advances in Medical Oncology|February 13, 2025
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitorsAhmet Yildirim, Mengting Wei, Yuan Liu, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitorsJacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Frontiers in Endocrinology|April 8, 2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer ImmunotherapyT Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, et al.
The Oncologist|June 7, 2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment OptionsKatherine Emilie Rhoades Smith, Jacqueline Theresa Brown, Limeng Wan, et al.
Urologic Oncology|April 25, 2022
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancerAgreen Hadadi, Katherine Er Smith, Limeng Wan, et al.
The Oncologist|March 13, 2020
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
The Oncologist|November 25, 2022
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsTony Z Zhuang, Deepak Ravindranathan, Yuan Liu, et al.
Cancer Treatment and Research Communications|May 24, 2021
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinibDylan J Martini, Meredith R Kline, Yuan Liu, et al.
Cancer Medicine|February 27, 2020
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitorsJulie M Shabto, Dylan J Martini, Yuan Liu, et al.
Cancer|April 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Yuan Liu, et al.
Therapeutic Advances in Medical Oncology|February 13, 2025
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitorsAhmet Yildirim, Mengting Wei, Yuan Liu, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitorsJacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
Pageof 4